| 6.95 -0.2 (-2.8%) | 08-04 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 9.89 | 1-year : | 11.21 |
| Resists | First : | 8.47 | Second : | 9.6 |
| Pivot price | 7.32 |
|||
| Supports | First : | 6.65 | Second : | 5.53 |
| MAs | MA(5) : | 7.11 |
MA(20) : | 7.57 |
| MA(100) : | 7.69 |
MA(250) : | 5.26  |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 29.3 |
D(3) : | 29.8 |
| RSI | RSI(14): 41 |
|||
| 52-week | High : | 12.43 | Low : | 1.95 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ IBRX ] has closed above bottom band by 21.6%. Bollinger Bands are 34.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.27 - 7.33 | 7.33 - 7.37 |
| Low: | 6.58 - 6.65 | 6.65 - 6.69 |
| Close: | 6.87 - 6.97 | 6.97 - 7.03 |
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
Tue, 04 Aug 2026
IBRX Stock Enters Heavy Catalyst Phase: Traders Brace For Key Anktiva Decision Amid Trump’s FDA Turmoil - Stocktwits
Tue, 04 Aug 2026
ImmunityBio (IBRX) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Tue, 04 Aug 2026
Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc - The National Law Review
Tue, 04 Aug 2026
Earnings Flash (IBRX) ImmunityBio Posts Q2 Net Loss $0.22 a Share, vs. FactSet Est of $0.08 Loss - marketscreener.com
Tue, 04 Aug 2026
Earnings Flash (IBRX) ImmunityBio, Inc. Reports Q2 Revenue $51.2M, vs. FactSet Est of $49.7M - marketscreener.com
Tue, 04 Aug 2026
ImmunityBio, Inc. (IBRX) Q2 2026 Earnings - 24/7 Wall St.
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1,050 (M) |
| Shares Float | 394 (M) |
| Held by Insiders | 62.4 (%) |
| Held by Institutions | 17.7 (%) |
| Shares Short | 134,400 (K) |
| Shares Short P.Month | 135,150 (K) |
| EPS | -0.86 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.83 |
| Profit Margin | 0 % |
| Operating Margin | -157.9 % |
| Return on Assets (ttm) | -34.4 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 167.6 % |
| Gross Profit (p.s.) | 0.13 |
| Sales Per Share | 0.13 |
| EBITDA (p.s.) | -0.24 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -294 (M) |
| Levered Free Cash Flow | -194 (M) |
| PE Ratio | -8.18 |
| PEG Ratio | 0 |
| Price to Book value | -8.38 |
| Price to Sales | 51.76 |
| Price to Cash Flow | -24.79 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|